FAQs about ATL1102 in MS
ATL1102 is an antisense inhibitor of CD49d being investigated as a potential therapy for relapsing forms of multiple sclerosis (MS). By blocking CD49d production, ATL1102 prevents immune cells from reaching the brain and spinal cord, which is expected to reduce MS-driving inflammation. In clinical trials, ATL1102 rapidly reduced the number of new lesions in the brain and also prevented these lesions from progressing into regions of permanent damage.
While promising results were obtained in a Phase 2a trial, and a Phase 2b trial was authorized by the U.S. Food and Drug Administration, there have been no updates about ATL1102’s development program for multiple sclerosis since 2017. It is not known if and when the medication will be further tested, or when it could be approved by the regulatory agency.
Clinical trials of ATL1102 in multiple sclerosis did not include participants who were pregnant or breastfeeding, so it is not known whether the treatment is safe in these situations.
Some participants in clinical trials saw benefits from ATL1102 in as little as two months after starting treatment. In a Phase 2a clinical trial that enrolled 77 patients with relapsing-remitting multiple sclerosis, a 54% reduction in the development of new brain lesions was observed after eight weeks. The number of lesions with active inflammation also was reduced by 88.5% at week 12.
Neither hair loss nor weight gain was reported as side effects of ATL1102 in multiple sclerosis clinical trials. Patients who experience unexpected side effects while on a new medication should talk with their healthcare team.